Home>Topics>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Morningstar's Most Popular

    Headlines

    Fri, 17 Apr 2015

    Johnson Apple Most Requested Fund Quotes Fidelity Contrafund Vanguard Health Care Vanguard Dividend Growth Fidelity Select Biotechnology Portfolio Vanguard 500 Index Most Requested Fund Analyses Vanguard Health Care Vanguard Dividend Growth Dodge & Cox Income

  2. BRIEF-Beihai Yinhe to acquire stake in biotech firm, plans fund with partners

    Headlines

    Fri, 17 Apr 2015

    * Says to acquire 60 percent stake in Jiangsu Decon Bio-Sci-Technology for 180 million yuan ($29.04 million)

  3. BRIEF-Sartorius Stedim Biotech buys U.K.-based BioOutsource

    Headlines

    Fri, 17 Apr 2015

    * Says BioOutsource has been operating in the biotechnology market since 2007, and in the last twelve months earned revenue of aobut 9 million euros ($9.70 million) with about 85 employees

  4. ReNeuron stem cell therapy shows long-term promise for stroke

    Headlines

    Fri, 17 Apr 2015

    LONDON, April 17 (Reuters) - A pioneering stem cell treatment for patients disabled by stroke has continued to show long-term promise in a clinical trial, the British biotech company behind the project said on Friday.

  5. BRIEF-BB Biotech Q1 net profit of CHF 379.4 million

    Headlines

    Fri, 17 Apr 2015

    * Net profit for Q1 amounted to 379.4 million Swiss francs ($397 million) Source text for Eikon: Further company coverage: ($1 = 0.9562 Swiss francs) (Gdynia Newsroom)

  6. A Push-Me, Pull-You Market

    Headlines

    Thu, 16 Apr 2015

    owned Maxy-G34, still brings value to the firm, over and above Maxygen's cash balance, which is quite large for a biotech of this size. Maxy-G34 is already in Phase II trials, and we think it still has a 30% chance of making it to the market

  7. UPDATE 1-Cancer drug flop sends Ipsen, Active Biotech shares skidding

    Headlines

    Thu, 16 Apr 2015

    LONDON, April 16 (Reuters) - Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to...

  8. Cancer drug flop sends Ipsen, Active Biotech shares skidding

    Headlines

    Thu, 16 Apr 2015

    LONDON, April 16 (Reuters) - Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to...

  9. BRIEF-Active Biotech shares plummet after discontinuing tasquinimod in prostate cancer

    Headlines

    Thu, 16 Apr 2015

    * Active Biotech and Ipsen earlier on Thursday announced their decision to discontinue the development of tasquinimod in prostate cancer Further company coverage: (Reporting by Daniel Dickson)

  10. Actelion accelerates immunology push with MS drug trial

    Headlines

    Thu, 16 Apr 2015

    April 16 (Reuters) - Actelion, Europe's biggest biotechnology company, is accelerating its push into immunology with the launch of late-stage tests of a drug for multiple sclerosis.

« Prev12345Next »
Content Partners